UNSPSC 51314378: Phenylephrine/promethazine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.

UNSPSC 51314378 Phenylephrine/promethazine is a Commodity code that in practice covers the procurement of naloxone, deactivation systems for controlled substances, generic multi-source pharmaceuticals, and over-the-counter products by state and local health and human services agencies. State and local issuing bodies acquiring under this code include county health departments, state pharmacy benefit programs, and cooperative purchasing alliances serving multiple jurisdictions. The scope extends from acute-response medications (naloxone for overdose reversal) to routine pharmacy benefit management through direct-to-manufacturer and wholesaler-distributed channels, with vendors typically required to maintain FDA compliance, cGMP certification, Drug Supply Chain Security Act adherence, and specific insurance coverages including commercial general liability and professional liability.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida released IFB 60459723LAS on June 30, 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, response due July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026 to assess vendor capacity for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information on direct contracting capabilities outside traditional pharmacy benefit manager and group purchasing organization arrangements. The Minnesota Department of Administration's Office of State Procurement released RFP S1070000015802 through the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) on January 20, 2026 to establish multiple contracts for generic pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract awards effective July 1, 2026; evaluation weighting prioritized price competitiveness at 75 percent, with vendors required to maintain relationships with at least two of three authorized wholesalers and comply with 3 percent administrative fees and performance penalties.